SLC5A2 and diabetes mellitus: In light of the recent reports demonstrating improvements in cardiac function, aortic stiffness, and renal perfusion, it is plausible that SGLT2 inhibition will counteract the pathophysiological factors contributing to exercise impairment in diabetes (111–116).